1-225921246-C-CAG
Position:
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PVS1_StrongPM2PP5_Very_Strong
The NM_013328.4(PYCR2):c.758_759insCT(p.Leu254CysfsTer35) variant causes a frameshift change. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: not found (cov: 32)
Consequence
PYCR2
NM_013328.4 frameshift
NM_013328.4 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 6.27
Genes affected
PYCR2 (HGNC:30262): (pyrroline-5-carboxylate reductase 2) This gene belongs to the pyrroline-5-carboxylate reductase family. The encoded mitochondrial protein catalyzes the conversion of pyrroline-5-carboxylate to proline, which is the last step in proline biosynthesis. Alternatively spliced transcript variants have been described for this gene. [provided by RefSeq, Nov 2012]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most 50 bp of the penultimate exon, not predicted to undergo nonsense mediated mRNA decay. Fraction of 0.213 CDS is truncated, and there are 2 pathogenic variants in the truncated region.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 1-225921246-C-CAG is Pathogenic according to our data. Variant chr1-225921246-C-CAG is described in ClinVar as [Likely_pathogenic]. Clinvar id is 286401.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PYCR2 | NM_013328.4 | c.758_759insCT | p.Leu254CysfsTer35 | frameshift_variant | 6/7 | ENST00000343818.11 | NP_037460.2 | |
PYCR2 | NM_001271681.2 | c.536_537insCT | p.Leu180CysfsTer35 | frameshift_variant | 5/6 | NP_001258610.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PYCR2 | ENST00000343818.11 | c.758_759insCT | p.Leu254CysfsTer35 | frameshift_variant | 6/7 | 1 | NM_013328.4 | ENSP00000342502 | P1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 genomes
Cov.:
32
GnomAD4 exome Cov.: 31
GnomAD4 exome
Cov.:
31
GnomAD4 genome Cov.: 32
GnomAD4 genome
Cov.:
32
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:4
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:3
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jul 26, 2023 | Frameshift variant predicted to result in protein truncation, as the last 67 amino acids are replaced with 34 different amino acids, and other loss-of-function variants have been reported downstream in HGMD; Not observed at significant frequency in large population cohorts (gnomAD); Has not been previously published as pathogenic or benign to our knowledge - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Mar 13, 2022 | This sequence change creates a premature translational stop signal (p.Leu254Cysfs*35) in the PYCR2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 67 amino acid(s) of the PYCR2 protein. For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the PYCR2 protein in which other variant(s) (p.Arg266*) have been determined to be pathogenic (PMID: 27130255, 27860360, 30369941, 31487502). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. ClinVar contains an entry for this variant (Variation ID: 286401). This variant has not been reported in the literature in individuals affected with PYCR2-related conditions. This variant is not present in population databases (gnomAD no frequency). - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Mar 07, 2016 | - - |
Hypomyelinating leukodystrophy 10 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Nov 13, 2023 | Variant summary: PYCR2 c.757_758dupCT (p.Leu254CysfsX35) results in a premature termination codon, predicted to cause a truncation of the encoded protein. Although nonsense mediated decay is not expected, this variant affects a region where other pathogenic variant(s) have been observed in ClinVar. The variant was absent in 251136 control chromosomes. To our knowledge, no occurrence of c.757_758dupCT in individuals affected with Hypomyelinating Leukodystrophy 10 and no experimental evidence demonstrating its impact on protein function have been reported. Three submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at